Add like
Add dislike
Add to saved papers

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution.

Blood 2020 January 14
Follicular lymphoma B cells undergo continuous somatic hypermutation (SHM) of their immunoglobulin variable region genes, generating a heterogeneous tumour population. SHM introduces DNA sequences encoding N-glycosylation sites Asparagine-X-Serine/Threonine (N-gly sites) within the V-region that are rarely found in normal B cell counterparts. Unique attached oligomannoses activate B cell receptor signalling pathways following engagement with calcium-dependent lectins expressed by tissue macrophages. This novel interaction appears critical for tumour growth and survival. To elucidate the significance of N-gly site presence and loss during ongoing SHM, we tracked site behaviour during tumour evolution and progression in a diverse group of patients through next-generation sequencing. A hierarchy of subclones was visualised through lineage trees based on SHM semblance between subclones and their discordance from the germline sequence. We observed conservation of N-gly sites in >96% of subclone populations within and across diagnostic, progression and transformation events. Rare N-gly-negative subclones were lost or negligible from successive events in contrast to N-gly-positive subclones which could additionally migrate between anatomical sites. Ongoing SHM of the N-gly sites resulted in subclones with different amino acid compositions across disease events, yet the vast majority of resulting DNA sequences still encoded for an N-gly site. The selection and expansion of only N-gly-positive subclones is evidence of the tumour cells dependence on sites despite the changing genomic complexity as the disease progresses. N-gly sites were gained in the earliest identified lymphoma cells, indicating they are an early and stable event of pathogenesis. Targeting the inferred mannose-lectin interaction holds therapeutic promise.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app